Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|ARID1A loss||Her2-receptor positive breast cancer||resistant||AZD8055||Preclinical - Cell culture||Actionable||In a preclinical study, ERBB2 (HER2) positive breast cancer cells with ARID1A loss demonstrated resistance to AZD8055 in culture (PMID: 27172896).||27172896|
|ARID1A loss||breast cancer||sensitive||AZD8055 + MK2206||Preclinical - Cell culture||Actionable||In a preclinical study, breast cancer cells with loss of ARID1A demonstrated restored sensitivity to AZD8055 when additionally treated with MK2206 in culture (PMID: 27172896).||27172896|
|ARID1A loss||Her2-receptor positive breast cancer||resistant||Trastuzumab||Preclinical - Cell culture||Actionable||In a preclinical study, ERBB2 (HER2) positive breast cancer cells with ARID1A loss demonstrated resistance to Herceptin (trastuzumab) in culture (PMID: 27172896).||27172896|
|ARID1A loss||colon cancer||predicted - sensitive||unspecified PD-L1 antibody||Preclinical - Cell line xenograft||Actionable||In a preclinical study, ARID1A-deficient colon cancer xenograft models demonstrated an increased response to treatment with an anti-PD-L1 antibody compared to controls (PMID: 29736026).||29736026|
|ARID1A loss||ovarian clear cell carcinoma||predicted - sensitive||JQ1||Preclinical - Cell culture||Actionable||In a preclinical study, knockout of ARID1A in ovarian clear cell carcinoma cell lines resulted in increased sensitivity to growth inhibition by JQ1 compared to cells with wild-type ARID1A in culture (PMID: 29760405).||29760405|
|ARID1A loss||ovarian cancer||predicted - sensitive||unspecified PD-L1 antibody||Preclinical||Actionable||In a preclinical study, an ARID1A-deficient orthotopic ovarian cancer mouse model treated with a PD-L1 antibody demonstrated improved survival and greater decreased tumor volume compared to those treated with control (PMID: 29736026).||29736026|